Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

2015; Elsevier BV; Volume: 125; Issue: 16 Linguagem: Inglês

10.1182/blood-2014-10-606038

ISSN

1528-0020

Autores

John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien,

Tópico(s)

Immunodeficiency and Autoimmune Disorders

Resumo

Key Points Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. Toxicity diminished over time with respect to grade ≥3 cytopenias, fatigue, infections, and adverse events leading to discontinuation.

Referência(s)